Dociparstat sodium, also known as DSTAT, is an investigational, intravenous treatment in development as a first-line therapy in acute myeloid leukemia (AML). Clinical studies have suggested that the combination of DSTAT with standard chemotherapy may improve outcomes for individuals with this life-threatening disease.

How does DSTAT work in AML?

DSTAT may enhance eradication of leukemic blasts and dormant leukemic stem cells by flushing them out of the bone marrow and making them more sensitive to chemotherapy, reducing the potential for eventual relapse. Clearance of leukemic stem cells may translate to increased depth of response and improved long-term outcomes for patients with AML. Specifically, DSTAT may:

  • Mobilize AML cells out from the protective bone marrow environment, rendering them more susceptible to chemotherapya
  • Sensitize treatment-resistant AML cells for tumor cell deatha
  • Bind to multiple proteins to reduce AML chemotherapy resistance and enhance platelet recovery after chemotherapya

DSTAT has been shown to bind to platelet factor 4, which may help with hematologic recovery in patients with AML.

Read more about DSTAT and results from a Phase 2 clinical trial here.

What’s next for DSTAT?

DSTAT has received Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration for the treatment of AML.

Chimerix plans to initiate a Phase 3 study of DSTAT in AML in mid-2020.

References: aZhang 2012 JBC 287(8); Kovacsovics 2018 Blood Adv 2(4); Yasinska 2018 Oncoimmunology 7(6); Rao 2010 Am J Physiol Cell Physiol 299; Zheng 2016 Am J Cell and Mol Bio 56(1); Griffin 2014 Am J Resp Cell and Mol Bio 50(4); Lakshmi 2010 J Biomed Mat Res 95(1); Yu 2005 Blood 105(9);  Lapierre 1996 Glycobiology 6(3); Tavor 2005 Blood 106(6); Kummarapurugu 2018 JBC 293(32)